Onconetix, Inc. (ONCO)
NASDAQ: ONCO · IEX Real-Time Price · USD
0.173
+0.012 (7.20%)
At close: Jul 26, 2024, 4:00 PM
0.167
-0.006 (-3.24%)
After-hours: Jul 26, 2024, 7:46 PM EDT
Onconetix Revenue
Onconetix had revenue of $700.43K in the quarter ending March 31, 2024. This brings the company's revenue in the last twelve months to $758.90K. In the year 2023, Onconetix had annual revenue of $58.47K.
Revenue (ttm)
$758.90K
Revenue Growth
n/a
P/S Ratio
5.08
Revenue / Employee
$63,242
Employees
12
Market Cap
3.85M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 58.47K | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Venus Concept | 73.30M |
Regional Health Properties | 17.39M |
iSpecimen | 9.27M |
Avinger | 7.62M |
Sintx Technologies | 2.78M |
Fresh2 Group | 2.35M |
ONCO News
- 12 days ago - Onconetix Announces Closing of Warrant Exercise for $1.11 Million Gross Proceeds - GlobeNewsWire
- 15 days ago - Onconetix Announces Exercise of Warrants for $1.11 Million Gross Proceeds - GlobeNewsWire
- 5 months ago - Onconetix Announces Appointment of Seasoned Biotech Executives Dr. Ajit Singh and Dr. Thomas Meier to Its Board of Directors - GlobeNewsWire
- 7 months ago - Onconetix™ Chief Executive Officer Dr. Neil J. Campbell Issues Letter to Shareholders - GlobeNewsWire
- 7 months ago - Blue Water Biotech Acquires Proteomedix as Part of Transformation to Commercial Stage Oncology Company; Announces Name Change to Onconetix™ - GlobeNewsWire
- 9 months ago - Blue Water Biotech Signs Non-Binding Term Sheet to Acquire a Commercial Stage Oncology Company - GlobeNewsWire
- 9 months ago - Blue Water Biotech Announces It Has Regained Compliance with Nasdaq Listing Rule 5250(c)(1) - GlobeNewsWire
- 9 months ago - Blue Water Biotech Issues Letter to Shareholders - GlobeNewsWire